Journal · Updated 2026-08-11
The Compounded GLP-1 Enforcement Record: Every FDA Wave, Dated — and What the Letters Actually Cite
By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify
The short answer
The FDA ran the most aggressive enforcement campaign in compounded GLP-1 history across late 2025 and 2026 — and its target, in the agency's own letters, is less the act of compounding than how compounded semaglutide and tirzepatide are marketed. The dated spine: a 2025 wave of warning and untitled letters over compounded-drug advertising (counts across sources run from the fifties to roughly eighty); a February 2026 announcement by the FDA Commissioner naming misleading advertising, unauthorized importation, and high-volume interstate shipping as targets; thirty warning letters to telehealth companies on March 3, 2026 — the largest single action of its kind; an April 30, 2026 proposal to permanently remove semaglutide, tirzepatide, and liraglutide from the 503B bulks list, which would close the outsourcing-facility pathway most large compounded programs run on; and a second wave of twenty-five letters on June 8, 2026 that specifically cited companies for concealing which pharmacy actually makes their drugs. The comment period on the 503B proposal closed July 30, 2026; as of this page's August 11 capture, no final rule has issued — compounded GLP-1s are not banned, and anyone saying otherwise is ahead of the record. Here is each entry, what the letters actually say, and the checklist a buyer should run because of them.
The record, in order
September–fall 2025 — the first wave
The FDA's prescription-drug-promotion office issued a high volume of warning and untitled letters through late 2025 as part of a broader push on direct-to-consumer drug advertising. Law-firm analyses count fifty-eight letters addressing compounded GLP-1 claims within that push; trade and industry summaries put the GLP-1-specific figure between roughly fifty and eighty depending on what is counted. The through-line in the citations: equivalence claims — marketing compounded products as if they were the FDA-approved drugs.
January–February 2026 — a quality letter, an approved tablet, and a named enforcement agenda
Three entries land close together. A January 16 warning letter to a 503A pharmacy (published February 10) cited insanitary conditions and strength, quality, and purity noncompliance in its compounded products, including GLP-1s — a manufacturing-quality citation, not a marketing one, and a reminder that both failure modes exist. The same month, the manufacturer's FDA-approved once-daily oral semaglutide tablet launched, removing the shortage-era rationale for mass-compounded semaglutide tablets. And in February the FDA Commissioner announced targeted enforcement on compounded GLP-1s by name: misleading advertising, unauthorized importation of active ingredients, and pharmacies shipping more than twenty prescriptions out of state.
March 3, 2026 — thirty letters in one day
The agency sent warning letters to thirty telehealth companies for false or misleading claims about compounded semaglutide and tirzepatide — the largest single enforcement action against compounded GLP-1 marketing on record. The cited patterns: claiming compounded drugs were equivalent to the approved medications, and obscuring where the products actually came from. Six days later, one of the market's largest telehealth sellers announced a partnership to sell the branded product and cease advertising compounded semaglutide except where medically necessary — the clearest market signal of the year about which direction the pressure points.
April 30, 2026 — the structural move: the 503B bulks-list proposal
The FDA proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the list of bulk substances that 503B outsourcing facilities may compound from. Finalized, this closes the factory-scale pathway that subscription-volume compounded programs depend on — a 503A pharmacy compounding per-prescription cannot supply tens of thousands of subscribers. The same spring, the agency restated that compounders cannot produce what amounts to a copy of a commercially available drug in the same or similar strength. The Federal Register notice (docket 2026-08552, published May 1) set the original comment deadline at the end of June 2026; the period was extended once and closed July 30, 2026. As of our August 11 capture: no final rule, no published decision timeline. Three legal facts from the primary documents worth holding precisely: the agency's stated basis is that no clinical need exists for bulk compounding where approved products are available — and its own guidance is explicit that affordability and insurance access do not constitute clinical need; the shortage-list pathway had already closed for these molecules (tirzepatide's shortage resolved in 2024, semaglutide's in February 2025), which is why the bulks-list question is the last door; and liraglutide remains on the shortage list as of the proposal, so 503B compounding of liraglutide continues lawfully for now despite its inclusion in the exclusion proposal. Scale context from industry analyses: compounded product reached roughly thirty percent of US GLP-1 supply at the 2024 peak — the size of the market this rule would reshape. The February 2026 escalation carried its intent in its title: "FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs." The proposal is the single most consequential open question hanging over every compounded price in our database, and when it resolves, this page and the pricing pages update the same day, with the change logged.
June 8, 2026 — twenty-five more letters, and the pharmacy-disclosure citation
The second 2026 wave brought the two-wave total to at least fifty-five. The public letters are specific in ways a buyer should read: one cited a seller whose product photos carried its own brand on the label, suggesting it was the compounder when it was not; the same letters cite the recurring equivalence framing — "the active ingredient in" the branded drugs — as misbranding under the misleading-advertising provisions of federal drug law; and analyses of the wave note the agency specifically cited companies that never disclose which pharmacy compounds their product. That last citation is the one this site was structurally built for: our provider records carry a named-pharmacy field precisely because an undisclosed pharmacy is unverifiable, and programs that will not name theirs are flagged in the database and excluded from the trust-dependent recommendations.
The safety numbers underneath the enforcement
By early 2025 the FDA had logged more than four hundred fifty-five adverse-event reports linked to compounded semaglutide and more than three hundred twenty linked to compounded tirzepatide, with hospitalizations among them — and the dominant traceable cause was not exotic contamination but dosing error: patients drawing their own doses from multidose vials, sometimes at amounts exceeding approved labeling, with no one checking the math. That failure mode is the buyer's to control. The dose encyclopedia — every tirzepatide step from 2.5 mg and every semaglutide step, with the units-to-milligrams conversion that most at-home errors trace to — exists for the arithmetic, the side-effect A–Z for knowing what warrants a call, and no comparison-shopping decision on this site matters more than drawing the right dose.
The checklist the record writes for you
Every citation pattern above converts to a pre-purchase check. Named pharmacy: if the program will not tell you which licensed pharmacy compounds its product, the FDA's June letters explain why that ends the evaluation — run the fifteen-minute verification workflow on the name you get. No equivalence claims: a program calling its product "FDA-approved" or flatly "the same as" the branded drug is repeating the exact language the letters cite; compounded drugs are legal under specific conditions and never FDA-approved, and a seller blurring that is telling you how it handles every other fact. A plan for the 503B question: ask what happens to your supply if the bulks-list exclusion finalizes — a program with a real pharmacy network has an answer; a program with a secret one does not, and the full contingency plan scripts the three questions and the transition math. Dose discipline: insist on titration instructions in writing and check them against the published schedules — the per-dose encyclopedia pages print the label's own progression at every step. The enforcement record is not a reason to panic out of a working, verified program — it is the most authoritative buyer's guide ever written for this market, one violation at a time.
Questions people ask
Are compounded semaglutide and tirzepatide banned as of August 2026?
No. The FDA proposed on April 30, 2026 to permanently remove semaglutide, tirzepatide, and liraglutide from the 503B bulks list — which would close the large-scale compounding pathway — and the comment period closed July 30, 2026, but as of this page's August 11 capture no final rule has issued and no decision timeline is published. Compounding under existing 503A/503B rules remains legal; the direction of regulatory travel is unmistakably narrower.
How many warning letters has the FDA sent over compounded GLP-1s?
At least 55 to telehealth companies across the two 2026 waves (30 on March 3, 25 on June 8), on top of a 2025 wave that sources count between roughly 50 and 80 letters depending on scope. The 2026 letters overwhelmingly cite marketing violations — equivalence claims and concealed pharmacy sources — rather than the act of compounding itself.
How do I check whether a specific company got an FDA warning letter?
Search the FDA's public warning-letters database (fda.gov, under inspections and compliance) for the company's legal name — not just its brand name, which may differ. Step 1 of our verification workflow covers finding the legal name; the letters themselves are public and list the specific claims cited.
What should I do if my program's pharmacy is never named?
Treat it as disqualifying. The FDA's June 2026 letters specifically cited companies that conceal which pharmacy compounds their product, because an unnamed pharmacy cannot be verified for licensure, inspection history, or recalls. Our database flags undisclosed-pharmacy programs and the verification guide shows what a named pharmacy lets you check in fifteen minutes.
Were the 2026 actions about safety problems or marketing problems?
Mostly marketing — false equivalence and source concealment under federal misbranding provisions — but not exclusively: a January 2026 letter to a 503A pharmacy cited insanitary conditions and strength/quality/purity failures, and FDA adverse-event tallies (455+ for compounded semaglutide, 320+ for compounded tirzepatide by early 2025) trace largely to at-home dosing errors with multidose vials. Both failure modes are real; the buyer controls the second one.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.